We scan new podcasts and send you the top 5 insights daily.
Tom reads the hazard ratios as a near-exact stepwise drop: 0.71 for pembrolizumab versus cystectomy and 0.40 for EV plus pembrolizumab, with each component apparently contributing about 0.3. He cautions the 85-patient arms are small, but says the EFS curves visually support this additive pattern.
As neoadjuvant enfortumab vedotin plus pembrolizumab (EVP) achieves high pathologic complete response rates in MIBC, a critical question emerges: is adjuvant EVP necessary for everyone? Continuing treatment in patients who are already cancer-free post-surgery may offer no extra benefit while increasing toxicity.
Unlike traditional chemotherapy, the EV+pembrolizumab combination is producing a "tail on the curve" in survival data. This indicates a significant minority of patients with metastatic bladder cancer are achieving durable, long-term responses—a phenomenon previously unseen and a paradigm shift for the disease.
Anders notes that in the primary KEYNOTE-905 analysis the control arm had grade 3 or higher adverse events in the 40-50% range, likely from surgery alone. That makes the 44% neoadjuvant rate with EV plus pembrolizumab look less alarming than a simple cross-arm comparison might suggest.
The combination of enfortumab vedotin and pembrolizumab is not just improving median survival in metastatic bladder cancer; it's creating a "tail on the curve," suggesting a subset of patients may achieve long-term durable responses, a rarity in this advanced setting.
Tom says perioperative EV-pembrolizumab produced hazard ratios of 0.53 and 0.60 versus Niagara's 0.68 and 0.75, with path CR jumping to 55%. Rob still expects Niagara to remain relevant until EV is licensed and reimbursed in many countries. Access barriers, not just efficacy, shape near-term standard of care.
An expert speculates that the durable responses and plateauing four-year survival curve from the EV302 trial indicate a potential cure rate of 30% in metastatic bladder cancer, a dramatic improvement over historical outcomes of 5-10%.
While both the B15 (EV Pembro) and Niagara (Gem-Cis-Durvalumab) trials were positive, B15 demonstrated a significantly higher pathologic complete response rate (56% vs 37%) and more favorable hazard ratios for survival endpoints. This suggests EV Pembro is the "more positive" regimen and likely the preferred standard of care.
With therapies like Enfortumab Vedotin + Pembrolizumab (EVPembro) inducing a pathological complete response (PathCR) in 60% of patients, many undergo radical cystectomies only to find no residual cancer. This success rate is driving trials for bladder-sparing approaches like active surveillance.
The demonstrated superiority of the enfortumab vedotin (EV) and pembrolizumab combination over platinum chemotherapy has effectively made the Galski criteria, used for determining cisplatin eligibility, irrelevant. This marks a major paradigm shift in how frontline bladder cancer is approached, moving beyond platinum-based decisions.
In cisplatin-ineligible muscle-invasive bladder cancer, neoadjuvant enfortumab vedotin plus pembrolizumab demonstrated a 57% pathologic complete response rate in the KEYNOTE-905 trial. This is an unprecedented result, significantly higher than any previously studied regimen and signals a major shift in perioperative treatment.